Radiation therapy improves cancer cure rates by killing cancer cells but it also contributes to long-term side effects in cancer survivors by unintentionally damaging normal organs such as the intestine. This research will what side effects patients with cancer experience, if high dose vitamin C helps reduce these side effects, and if high dose vitamin C increases the survival of patients with pancreatic cancer. We will meet with patients during the study to better understand their experience during their cancer treatment. In the long term, our research could provide a new way help cancer survivors avoid many permanent side effects of cancer treatments.

Start Date31 Dec 2025

Sponsor / Collaborator

The Holden Comprehensive Cancer Center

NCT06823999

/ Not yet recruitingPhase 4IIT

Effect of Vitamin C in the Prevention and Treatment for Bruises in Patients with Ischemic Stroke: a Double-blind Randomized Control Trial

Background Over the past few decades, significant advances have been made in the diagnosis and treatment of strokes. Most studies focus on functional recovery in stroke patients. In addition to motor function, there are many symptoms may affect function and quality of life in stroke patients. Bruises are caused by damage to the skin that causes blood to drain out of the capillaries and accumulate in the connective tissue of the skin or subcutaneous tissue. The study on non-motor syndrome in ischemic stroke patients found that 25.8% of ischemic stroke patients had bruises and 17.7% of bruises were unexplained bruises. In addition to the physiological and emotional effects on stroke patients, bruises may increase infection risk and affect stroke patient outcomes. Vitamin C is a natural antioxidant discovered in 1747 to treat and prevent scurvy. Vitamin C can reduce gum bleeding and prevent colon bleeding after a polypectomy. Vitamin C has been reported to reduce brain edema around brain injury and decrease mortality in patients with traumatic brain injury. Dehydroascorbic acid decreases infarct volume in mice with middle cerebral artery occlusion. Investigators hypothesized that administration of vitamin C to patients with acute ischemic stroke patients would decrease the risk of bleeding and enhance its resolution. Investigators also hypothesized that vitamin C injection could minimize infarct volume and improve outcomes in ischemic stroke patients. The aims of the study include: 1. To investigate whether vitamin C injections can reduce bruising risk and enhance bruising resolution. 2. To explore whether vitamin C injections in the acute phase of stroke can improve the prognosis of ischemic stroke patients.
Methods This is a prospective, double-blind, randomized controlled study. All patients admitted to the hospital under the diagnosis of ischemic stroke and stroke was confirmed by Magnetic Resonance imaging (MRI) or brain computed imaging (CT) and aged between 20 and 85 years were invited to participate in the study. Investigators excluded patients who had these diseases: cancer receiving chemotherapy, end stage renal disease receiving dialysis, autoimmune disease, hematological disease, Glucose-6-phosphatase disease, gouty arthritis, and a lack of informed consent.
During the study period, all patients who met the inclusion and exclusion criteria were invited to participate in the study. After informed consent, participants were randomly assigned to the experimental group or the control group. All participants underwent NIHSS evaluation and a detailed dermatological examination on the day of hospitalization. After enrollment, the experimental group received 4 mg Vitamin C injection per day for 4 days, while the control group received the same volume of normal saline injection per day for 4 days. Researchers evaluate participant skin condition (including bruises number and size, color) every day during hospitalization, and up to 1 month after stroke. Investigators evaluate NIHSS at discharge and follow-up functional outcome (mRS) up to 3 months after stroke onset.
Analysis Rate shows bruise percentage. Chi square or Fisher exact test was applied to compare the difference in bruises between two groups. Logistic regression was used to compare bruise risk between groups. Wilcoxon rank sign test was used to analyze stroke severity and outcome between two groups.

Start Date01 Aug 2025

Sponsor / Collaborator

Chiayi Christian Hospital

ChiCTR2500098694

/ SuspendedNot ApplicableIIT

Study on relative bioavailability of liposome vitamin C

Start Date15 Apr 2025

Sponsor / Collaborator

The First People's Hospital of Kunshan

100 Clinical Results associated with Ascorbic Acid

100 Translational Medicine associated with Ascorbic Acid

100 Patents (Medical) associated with Ascorbic Acid

192,908

Literatures (Medical) associated with Ascorbic Acid

31 Dec 2025·Journal of the International Society of Sports Nutrition

Survey of nutritional intake status in college baseball players

Article

Author: Aoyama, Yuka ; Tanaka, Mamoru ; Seguchi, Manato ; Iio, Yoko ; Kozai, Hana ; Mori, Yukihiro ; Ito, Morihiro

BACKGROUND:

Diet is closely related to exercise performance. To improve athletes' performance and manage their condition, it is important to get sufficient energy and various nutrients. Thus, it is necessary that athletes understand their nutritional intake status to improve performance and maintain health. This study aimed to explore the nutritional intake status of college baseball players using the Food Frequency Questionnaire (FFQ). Furthermore, the characteristics of their nutritional intake status with respect to athletic performance were evaluated. The result of this studyprovide an opportunity for many under-developed college athletes with irregular lifestyles to recognize and improve their nutritional problems.

METHODS:

In October 2022, a questionnaire survey of 116 male members of a college baseball club was conducted. Of whom, 100 (94.3%) members responded to the survey and 92 (92.0%) provided valid responses. The survey items included basic characteristics such as college grade and type of living arrangement, and information on living conditions, e.g. whether the participant ate breakfast. Nutritional intake was evaluated using the FFQ. Players were divided into the first (regular players in official games), second (bench players in official games), third (players who may join the second or higher team in the future), and fourth teams (players who do not belong to the first to third teams); these categories were used as a marker of performance level. The Kruskal-Wallis test was used to analyze the association between the performance levels of baseball players and the intake of each nutrient and food group obtained by the FFQ. For items that showed a significant association, inter-group comparison was performed using the Dunn-Bonferroni method.

RESULTS:

Carbohydrate intake was greater in the second team compared with the third and fourth teams; saturated and monounsaturated fatty acid intake was higher in the third team compared with the fourth team. Calcium, zinc, copper, manganese, insoluble dietary fiber, iodine, and molybdenum intake was higher in the second team compared with the fourth team. Intake of grains, sugar, dairy, and total energy was significantly higher in the second team compared with the fourth team. However, the protein intake ratio was significantly lower in the second team compared with the fourth team. Overall, energy deficiency and associated deficiencies in protein, fat, and carbohydrate were observed, in addition to dietary fiber and calcium deficiencies. The intake of several food groups appeared inadequate, such as potatoes, beans, vegetables, fruits, eggs, milk, and fats.

CONCLUSIONS:

The study showed deficiencies in the amount of energy and nutrients such as protein, fat, and carbohydrate in college baseball players. Differences in the intake of carbohydrate, calcium, and insoluble dietary fiber among different performance levels were observed, with significantly higher intake of carbohydrate, calcium, and insoluble dietary fiber in the second team. Implementing organized and strategic remedial measures and athletes' identification of nutritional problems are vital to overcome nutritional and energy deficiencies. This study provides useful information for the development of strategies to support nutritional intake in college baseball players.

31 Dec 2025·Green Chemistry Letters and Reviews

Guaiazulene and aureusidin inhibit metabolic adaptability and virulence in Candida albicans by targeting the glyoxylate cycle under alternative carbon conditions

Author: Zhao, Zhongming ; Mallik, Saurav ; Shastry, Rajesh P. ; Rao, R. Shyama Prasad ; Ghate, Sudeep D. ; Giri, Jayant

Several Candida species such as C. albicans and C. auris have emerged as formidable multidrug-resistant pathogens, posing significant challenges to global healthcare.C. albicans can rapidly adapt its metabolism under nutrient-limited conditions, such as low-carbon environments, leading to virulence and drug resistance.Therefore, identifying novel compounds that can disrupt this metabolic adaptability is crucial for developing effective therapeutic strategies against this elusive pathogen.In this study, we first employed an in-silico dynamics approach to investigate the inhibitory effects of guaiazulene and aureusidin on C. albicans metabolic adaptability and virulence.By employing mol. docking and mol. dynamics simulations, we demonstrated that these compounds strongly interacted with crucial enzymes involved in the glyoxylate cycle, impairing their catalytic functions.Guaiazulene exhibited the highest binding affinity for malate synthase and isocitrate lyase, with a docking score of -8.5 and -9.3 kcal/mol, resp.The ADME properties of these mols. were also examined to evaluate the pharmacol. parameters.Furthermore, we investigated the impact of guaiazulene and aureusidin on C. albicans growth and biofilm formation.Our findings indicated that the targeting the glyoxylate cycle represents a promising strategy to counteract the metabolic adaptability of C. albicans and enhance the efficacy of antifungal agents.

31 Dec 2025·Journal of Maternal-Fetal & Neonatal Medicine

Assessing the relationship between serum vitamin A, C, E, D, and B12 levels and preeclampsia

Article

Author: Hu, Zhenhua ; Yang, Wenjiao ; Gu, Weirong

OBJECTIVE:

Micronutrients play an important role in maintaining physiological functions while preventing complications associated with pregnancy. The main aim of this study was to evaluate the possible associations between vitamins A, C, D, E, B12, and preeclampsia using a retrospective analytical approach.

METHODS:

This retrospective study enrolled pregnant women who attended routine antenatal checkups between January 2021 and January 2023 at the Obstetrics and Gynecology Hospital of Fudan University. One thousand pregnant women aged 18-50 years whose serum vitamin assessments were conducted during 12-20 weeks of gestation were enrolled. Inclusion criteria: women with preeclampsia, singleton pregnancies, and no previous history of hypertension or preeclampsia. Exclusion criteria: metabolic disorders, multiple pregnancies, and other specified exclusions. Approval of the hospital's ethics committee; all participants gave written informed consent. Demographic data analyzed include age, BMI, and gestational age, showing no significant differences in age span between groups (p > .05).

RESULTS:

In the preeclampsia group, the serum level of vitamin A stands at 1.08 ± 0.29 μmol/L, which is lower than the control group of 1.13 ± 0.31 μmol/L (p < .05). Mean serum levels of vitamin C in preeclampsia are 51.81 ± 13.15 μmol/L, which was lower than in the control group, where it was 59.67 ± 16.40 μmol/L (p < .05). The mean serum vitamin B12 level in preeclampsia is 158.28 ± 46.77 pmol/L, lower than the 165.61 ± 40.99 pmol in the control group (p < .05). The two groups had no significant difference in serum vitamin E and vitamin D levels (p > .05).

CONCLUSION:

Serum vitamins A, C, and B12 at 12 to 20 weeks of pregnancy might be important predisposing factors for preeclampsia. They can be used as indicators of preeclampsia severity and offer clinical detection even before the patient presents with symptoms.

News (Medical) associated with Ascorbic Acid

25 Mar 2025

·www.prnewswire.com

Mitsubishi Tanabe Pharma America Announces Publication of Preclinical Research on the Role of Edaravone in Mitigating TDP-43 Mislocalization in ALS

Results from this analysis were published in Free Radical Biology and Medicine JERSEY CITY, N.J., March 25, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of new preclinical research in Free Radical Biology and Medicine, highlighting the role of edaravone in mitigating TDP-43 mislocalization, a hallmark feature observed in more than 97% of sporadic amyotrophic lateral sclerosis (ALS) cases. The study, conducted using induced pluripotent stem cell (iPSC)-derived motor neurons from a single patient with ALS, demonstrated that edaravone significantly reduced the abnormal cytoplasmic accumulation of TDP-43, restoring its nuclear localization. This mislocalization is a key driver of neuronal dysfunction and degeneration in ALS, and suggests that edaravone may offer a varied therapeutic approach for ALS by targeting oxidative stress and TDP-43 mislocalization through distinct molecular pathways. "These findings help build upon our understanding of edaravone's potential effects in ALS," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA. "By modulating TDP-43 pathology and engaging molecular pathways linked to neurodegeneration, edaravone may play a broader role in ALS management than previously understood and should continue to be studied." "This study provides preclinical evidence that edaravone's MOA in ALS extends beyond its known antioxidant properties," said Satsuki Mikuriya, Research Scientist at MTPA and lead author of the study. Key findings from the study include: In ALS patient-derived neurons from a patient with ALS harboring a TDP-43 mutation, edaravone significantly reduced the cytoplasmic accumulation of TDP-43, restoring its nuclear localization. Unlike vitamin C, edaravone preserved neurite structures and reduced neurotoxicity, supporting a unique mechanism of action. Edaravone treatment induced significant changes in gene expression as early as six hours post-treatment, with key pathways related to protein degradation and neuroprotection. Edaravone's effects were associated with modulation of the SIRT1-XBP1 pathway, a key regulator of cellular stress responses, suggesting a broader role in ALS neuroprotection. This preclinical study was conducted using iPSC-derived motor neurons from a single ALS patient with a specific TDP-43 mutation (A382T) in an in vitro setting. Additional research in animal models and clinical settings (including those with other ALS-related mutations and patients with sporadic ALS) is needed to confirm these findings. Additionally, recent research has highlighted not only the toxic gain of function caused by TDP-43 aggregation but also the pathological sequences of TDP-43 loss of function due to its nuclear depletion. Further studies are required to explore how edaravone influences the loss of TDP-43 function. While the study provides important new insights into edaravone's potential role in ALS treatment, further research is needed to confirm its effects in larger, more diverse ALS models and to explore its long-term impact on disease progression. This analysis was funded and conducted by MTPA. Additional results can be found in the publication, titled, "Edaravone mitigates TDP-43 mislocalization in human amyotrophic lateral sclerosis neurons with potential implication of the SIRT1-XBP1 pathway." About Mitsubishi Tanabe Pharma America, Inc. Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit or follow us on X (formerly Twitter), Facebook and LinkedIn. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to Media inquiries: [email protected] SOURCE Mitsubishi Tanabe Pharma America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

28 Jan 2025

·www.prnewswire.com

Debut Unveils AI-powered Ingredient Discovery Platform to Fuel Biotech Innovation for All Beauty Brands Globally through Partner KDC/one

New discovery engine, BeautyORB™ by Debut, will create two novel, peak-performing biotech ingredients each year, giving beauty brands access to game-changing clinical claims and product innovation. Debut's new partnership with contract manufacturer KDC/one enables brands of all sizes to harness the power of biotech. SAN DIEGO, Jan. 28, 2025 /PRNewswire/ -- Debut, the biotech beauty leader, announced today the launch of BeautyORB™, an AI-powered innovation engine that provides a new way to discover novel ingredients for best-in-class claims for beauty brands, from a typical time horizon of several years to two Debut ingredients launched each year. The genomics-based AI platform, which is on par with pharmaceutical-grade technology, has already fueled the creation of groundbreaking ingredients addressing inflammaging, epidermal barrier repair and longevity, with brightening, anti-aging and scalp care ingredients already in the pipeline. Continue Reading Image Credit: Billy Economou, BE Studios "With our advanced AI platform and understanding of skin biology, we can rapidly create brand new ingredients through computational compound prediction. This allows us to activate specific aspects of skin biology while also discovering new or improved cellular pathways for enhanced clinical claims," said Joshua Britton, Ph.D, Founder and CEO of Debut. "We don't have to rely on an array of existing ingredients to test against specific claims, and we don't have to go into the field to find rare ingredients in plants. All this can be done at the click of a button, cutting out years from the innovation cycle and accessing ingredients that no one has seen before. We can turn on and off molecular pathways differently and use AI to discover what molecules can affect those pathways. The result is a rich, proven and growing pipeline of novel ingredients with the strongest clinical results for our customers, allowing brands to win on product performance rather than marketing". BeautyORB™ discovers new ingredients by screening 50 billion molecules for their ability to turn on cellular pathways within skin, a process that has never previously been possible in beauty. Debut's AI platform has already identified three novel, patented ingredients that achieve the highest beauty standards including scientifically-proven, clinically-tested and 100% bio-based ingredients that beat existing benchmarks. These ingredients include: DermCeutical InflammagePRO™: Best-in-class for inflammaging. Decreases inflammatory markers, supports the skin barrier and enhances elasticity. 15X better than niacinamide. DermCeutical Barrier RepairPRO™: Best-in-class for epidermal barrier repair. Defends the skin against damage from environmental aggressors. 30% better than vitamin C for skin damage repair. DermCeutical LongevityPRO™: Best-in-class for cellular longevity. Decreases markers of cellular senescence and helps maintain healthy skin cells. 2X better than vitamin C for skin health. "With BeautyORB™, we can develop ingredients that have the targeted responses we seek, using the same technology to find ingredients that fight disease. Our tool is another key step in the convergence of pharma and beauty. We are thrilled to partner with the industry leading contract manufacturer KDC/one to create finished products of the highest quality, in tandem with Debut's custom formulation business, BiotechXBeautyLabs™, to achieve our mission of reinventing product performance with the safest sustainability credentials. Our KDC/one partnership sets the stage for a global biomanufacturing revolution in beauty," said Britton. BeautyORB™ is the latest tool to emerge from Debut's ongoing commitment to lead the beauty industry's shift to biotech, creating a community of future-forward brands and product innovators that solve existing and emerging consumer needs. Using generative AI, BeautyORB™ delivers: More than 50 billion molecule possibilities 30,000 genes tested per molecule using omics technology 25,000 genes tested per second 21,000 molecules screened in silico per second for deep learning 200+ new biological pathways tested per molecule Over 60 million data points, with 100 million over the next 12 months About Debut The leader in biotech beauty Debut is pioneering the beauty industry's shift from traditionally sourced ingredients derived from petroleum and cultivation to high-performing and inherently sustainable biotech ingredients. As a fully vertically-integrated global company, Debut creates superior, scientifically-engineered, bio-based and clinically-proven products and brands at scale to benefit people and planet. Our mission is to create a new beauty standard based on potency, purity, and performance. About KDC/one Industry leading Contract Manufacturer KDC/one's Beauty & Personal Care manufacturing platform includes state-of-the-art facilities across North America, Europe, and Asia, allowing us to seamlessly deliver solutions for the complex production requirements of our global customers. With a global network of manufacturing, R&D, innovation hubs, and showrooms, KDC/one has end-to-end capabilities across formulation, design, packaging, and manufacturing to service a wide range of customer types, from start-up brands to multinational consumer companies. SOURCE Debut Biotechnology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

26 Dec 2024

·www.prnewswire.com

Researchers from Korea University Explore How Ascorbic acid and FGF4 Revolutionize Regenerative Medicine

Korean scientists discover a groundbreaking method to transform ordinary fibroblasts into mature cardiomyocytes SEOUL, South Korea, Dec. 26, 2024 /PRNewswire/ -- Researchers at Korea University have achieved a significant breakthrough in regenerative medicine. They have demonstrated how fibroblast growth factor 4 and Ascorbic acid, known as vitamin C, can induce the trans-differentiation of fibroblasts into functional cardiomyocytes. This discovery activates key cellular pathways and offers hope for developing treatments for cardiovascular diseases, the leading cause of death worldwide. Continue Reading This diagram illustrates how the combination of fibroblast growth factor 4 and ascorbic acid activates the JAK2-STAT3 signaling pathway, promoting the maturation of induced cardiomyocytes (iCMs). This approach effectively reprograms fibroblasts into cardiomyocytes with improved structure and function, offering exciting possibilities for regenerative medicine. Cardiovascular disease continues to lead as the primary cause of death across the globe, taking millions of lives every year. Damage caused by these diseases is particularly difficult to repair, since the heart has minimal ability to regenerate itself. But what if we could reprogram the body's own cells to restore damaged tissue? This groundbreaking question has been tackled by scientists at Korea University, led by Dr. Myeong-Hwa Song. The team has unveiled an innovative technique to convert fibroblasts—common connective tissue cells—into mature and functional induced cardiomyocytes (iCMs). Their method relies on combining fibroblast growth factor 4 (FGF4) with vitamin C, a pairing that accelerates cell maturation and enhances function. "Our findings bring us closer to transforming regenerative medicine into practical therapies," says Dr. Song, who is based at Korea University's Department of Cardiology and in Seoul, South Korea. "This research takes an important step toward using a patient's own cells to repair their heart." Direct cardiac reprogramming, a process that bypasses the intermediate stem cell stage, allows fibroblasts to be converted into iCMs. While this approach holds significant promise, scientists have struggled to produce mature and fully functional cardiomyocytes. The Korea University team addressed this hurdle by activating a critical cellular mechanism: the JAK2–STAT3 signaling pathway. Through their research, the scientists employed advanced techniques like RNA sequencing, fluorescence imaging, and electrophysiological testing. Their results revealed key improvements: better cell structure with well-defined sarcomeres and T-tubules, enhanced electrical activity with improved ion channel function, and a higher efficiency in generating mature, fully reprogrammed cardiomyocytes. Dr. Song explained that the JAK2-STAT3 pathway was crucial to these outcomes, enabling the induction of cells that closely mimic the structure and function of natural cardiomyocytes. This discovery, published in Experimental & Molecular Medicine on October 10, 2024, holds tremendous promise for regenerative medicine. By promoting mature cardiomyocytes from a patient's own tissue, it may one day be possible to repair damage from heart attacks or other cardiovascular conditions. Such an approach could reduce reliance on heart transplants and potentially revolutionize treatments for millions of patients. However, further studies are necessary to ensure this method is both safe and effective for clinical use. "We're thrilled with these results, but this is just the beginning," says Prof. Song. "More research will be required before we can bring this approach to patients. That said, the possibilities are incredibly exciting." If translated into therapy, this technique could provide a personalized solution for regenerating heart tissue, establishing a significant advance in combating cardiovascular disease. Reference Title of original paper: FGF4 and ascorbic acid enhance the maturation of induced cardiomyocytes by activating JAK2–STAT3 signaling Journal: Experimental & Molecular Medicine DOI: About Korea University College of Medicine Website: Contact: Yoo-Jung Lee +82 2 2286-1131 [email protected] SOURCE Korea University College of Medicine WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Cell Therapy

100 Deals associated with Ascorbic Acid

External Link

KEGG	Wiki	ATC	Drug Bank
D00018	Ascorbic Acid	G01AD03 S01XA15	DB00126

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Avitaminosis	Japan	NISSIN Pharmaceutical Co., Ltd.	15 May 1990
Ascorbic Acid Deficiency	Japan	neo CritiCare Phama Co., Ltd.	09 Sep 1985
Iron Overload	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Methemoglobinemia	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Scurvy	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nutritional and Metabolic Diseases	Phase 3	United States	Beth Israel Deaconess Medical Center, Inc.	09 Feb 2018
Shock, Septic	Phase 3	United States	Beth Israel Deaconess Medical Center, Inc.	09 Feb 2018
Colorectal Cancer	Phase 3	Belgium	Norgine Ltd.	01 Oct 2014
Colorectal Cancer	Phase 3	France	Norgine Ltd.	01 Oct 2014
Colorectal Cancer	Phase 3	Germany	Norgine Ltd.	01 Oct 2014
Colorectal Cancer	Phase 3	Italy	Norgine Ltd.	01 Oct 2014
Colorectal Cancer	Phase 3	Poland	Norgine Ltd.	01 Oct 2014
Colorectal Cancer	Phase 3	Spain	Norgine Ltd.	01 Oct 2014
Colorectal Cancer	Phase 3	United Kingdom	Norgine Ltd.	01 Oct 2014
Feeding and Eating Disorders	Phase 3	Brazil	EMS SA (Brazil)	01 Oct 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05555576 (Pubmed \| PLoS One)	Not Applicable	Musculoskeletal Pain	55	Vitamin C 1g twice a day	tznqyeqvce(qylcedlbyt) = pcsohyfiob paycrqqnnm (uuklmxwgia, 3.3 - 19.5)	Positive	31 Dec 2024
				Vitamin C (Placebo)	tznqyeqvce(qylcedlbyt) = uallpeyxby paycrqqnnm (uuklmxwgia, 1.5 - 16.0)
ESMO_ASIA2024	Not Applicable	Mucositis	60	Vitamin C and Zinc injections	prwlimsodu(tvqrvjgaly) = jpanibyvdt oxaqowsswa (ibdkpnivbs ) View more	Positive	07 Dec 2024
				vitamin C (Standard care)	prwlimsodu(tvqrvjgaly) = vboulpxhhv oxaqowsswa (ibdkpnivbs ) View more
ASH2024	Not Applicable	Chronic Myelomonocytic Leukemia	-	High dose ascorbate	gkrbkzvoqm(vispdleuet) = increased total 5hmC levels kzgjqiclbb (xhsgjvwdqw ) View more	-	07 Dec 2024
NCT02905578 (Pubmed \| Redox Biol)	Phase 2	Metastatic Pancreatic Cancer	-	Gemcitabine and nab-paclitaxel only	rtwitbgauv(ambkvfyyaz) = hiqfftpjna xjtlbllfin (zesrsrpild ) View more	-	01 Nov 2024
				Gemcitabine and nab-paclitaxel + Pharmacological ascorbate (P-AscH<sup>-</sup>)	rtwitbgauv(ambkvfyyaz) = gvnzxgeoaz xjtlbllfin (zesrsrpild ) View more
UEGW2024	Not Applicable	-	540	Elobixibat plus sodium picosulfate with magnesium citrate	iponjmzgvr(vflarmqvle): difference = -1.5 (95% CI, -4.8 to 1.6) View more	Positive	13 Oct 2024
				Split-dose 2-L polyethylene glycol with ascorbic acid
NCT04291508 (ASTER, CTgov)	Phase 2	Respiratory Failure \| Critical Illness \| Sepsis ... View more	488	Intravenous Acetaminophen (room temperature) (IV Acetaminophen-Active)	vkgjndfpgl(avpaijmcwb) = hugkdcvwjz lxuxjxljee (builgqhncg, 10.6) View more	-	27 Sep 2024
				Intravenous Vitamin C (refrigerated) (IV Vitamin C-Active)	vkgjndfpgl(avpaijmcwb) = gyspzhsyvn lxuxjxljee (builgqhncg, 9.5) View more
NCT01905150 (CTgov)	Phase 2	Pancreatic Cancer	34	VitaminC+G-FLIP-DM (G-FLIP Alone for 4 Weeks, Then G-FLIP+VitaminC. When DP Occurred, Then G-FLIP-DM+VitaminC)	siianzrolo(mdxmzdfmup) = lfudftvdvb zyyrrgerof (hhklkvwgjh, yaxgwbsevf - ubwxgpjema) View more	-	14 Aug 2024
				VitaminC+G-FLIP-DM+G-FLIP (G-FLIP+VitaminC. When DP Occurred, Then G-FLIP-DM+Vitamin C.)	siianzrolo(mdxmzdfmup) = cfqaozfybl zyyrrgerof (hhklkvwgjh, uicwnntqbz - rrrctoecwc) View more
EULAR2024	Not Applicable	Tendinopathy	72	Dietary supplement (chondroitin sulfate, type I collagen, vitamin C, manganese) + corticosteroid injection	qieuytebeu(ymppbmqfbg) = 100% in the diacerein group and 0% in the study group ijxkiabyxt (khepellzcc ) View more	Positive	05 Jun 2024
				Diacerein + corticosteroid injection
ATS2024	Not Applicable	Sepsis \| Shock, Septic	-	Hydrocortisone, Ascorbic Acid, and Thiamine (HAT) Therapy	qddlbpietf(evbopqrshv) = The use of HAT therapy did not increase incidence of gastrointestinal bleeding compared to placebo/SoC lrffjqzanq (zbdyosrzaq ) View more	-	19 May 2024
NCT04344184 (CTgov)	Phase 2	Kidney Diseases \| Acute Lung Injury \| COVID-19	47	L-ascorbic acid (Infusion)	rlpkbzljdh(tunkfurpfg) = rhtbhjaeqf vyzofbjxtc (rvepitbxkl, 0.811) View more	-	04 Apr 2024
				Placebo (Placebo)	rlpkbzljdh(tunkfurpfg) = bfifiajsxk vyzofbjxtc (rvepitbxkl, 0.714) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis